Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

BACKGROUND: This phase 2 multi-institutional study was designed to determine whether gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single-fraction SBRT in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Herman, Joseph M, Chang, Daniel T, Goodman, Karyn A, Dholakia, Avani S, Raman, Siva P, Hacker-Prietz, Amy, Iacobuzio-Donahue, Christine A, Griffith, Mary E, Pawlik, Timothy M, Pai, Jonathan S, O'Reilly, Eileen, Fisher, George A, Wild, Aaron T, Rosati, Lauren M, Zheng, Lei, Wolfgang, Christopher L, Laheru, Daniel A, Columbo, Laurie A, Sugar, Elizabeth A, Koong, Albert C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/
https://www.ncbi.nlm.nih.gov/pubmed/25538019
http://dx.doi.org/10.1002/cncr.29161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/
https://www.ncbi.nlm.nih.gov/pubmed/25538019
http://dx.doi.org/10.1002/cncr.29161

Ejemplares similares